Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640807 | 1.00 | CASP3 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL24580492 | 1.00 | CASP3 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL31506328 | 0.98 | KMT2A (0.47) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL8140875 | 0.89 | CASP3 (0.51) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL29696728 | 0.89 | MDM4 (0.47) | CASP3MDM4TP53TLR2 | |
| SCHEMBL30562127 | 0.88 | MDM4 (0.53) | CASP3MDM4TP53TLR2 | |
| SCHEMBL119565 | 0.87 | MDM4 (0.56) | CASP3MDM4TP53TLR2 | |
| SCHEMBL598209 | 0.87 | MDM4 (0.56) | CASP3MDM4TP53TLR2 | |
| SCHEMBL119575 | 0.87 | MDM4 (0.56) | CASP3MDM4TP53TLR2 | |
| SCHEMBL30802551 | 0.87 | MDM4 (0.56) | CASP3MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | CARMOT THERAPEUTICS INC. (US) | 2026-02-05 | — | — | US | claimed |
| CN-119978100-A | Tizepa Process for producing peptide | 四川吉晟生物医药有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119930788-A | Preparation method of Retatrutide | 四川吉晟生物医药有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119529056-A | Solid phase preparation method of telipopeptide | 福建基诺厚普生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-118147106-A | Preparation methods of enzyme, complex enzyme, immobilized enzyme and Tirzepatide | 深圳瑞德林生物技术有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118005767-A | Method for preparing Tirzepatide by combining solid and liquid | 柏佳薇(深圳)生物科技有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117024528-B | Preparation method of Retatrutide | 杭州信海医药科技有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-117024528-A | Preparation method of Retatrutide | 杭州信海医药科技有限公司 | 2023-11-10 | — | — | CN | claimed |
| EP-4724472-A2 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | disclosed |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | CARMOT THERAPEUTICS INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3774838-B9 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-12-10 | — | — | EP | disclosed |
| EP-3774838-B2 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-119978100-A | Tizepa Process for producing peptide | 四川吉晟生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119930788-A | Preparation method of Retatrutide | 四川吉晟生物医药有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-117024528-A | Preparation method of Retatrutide | 杭州信海医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4269422-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116615411-A | Process for producing peptide compound containing N-substituted amino acid residue | 中外制药株式会社 | 2023-08-18 | — | — | CN | disclosed |
| US-11560402-B2 | Method for cleavage of solid phase-bound peptides from the solid phase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-3774838-B1 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560402-B2 | Method for cleavage of solid phase-bound peptides from the solid phase | VIP, PTMS, CTRC | CASP3 231/4885MDM4 4329/4885TP53 1190/4885 |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | GLP1R, GIPR, GRPR | CASP3 1940/4885MDM4 3842/4885TP53 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.